What are the side effects of Ruxolitinib cream-Opzelura?

Ruxolitinib cream (Ruxolitinib cream)-Opzelura is mainly used to treat atopic dermatitis (AD) and non-segmental vitiligo. Although this drug has shown good clinical efficacy, its use may also be accompanied by some side effects.

In clinical studies, the more common adverse reactions in patients with atopic dermatitis include nasopharyngitis, diarrhea and bronchitis. These adverse reactions are usually mild and resolve gradually after discontinuation of use or dose adjustment. However, some patients may also develop ear infections, elevated eosinophil counts, folliculitis, tonsillitis, and rhinorrhea. Although these side effects are relatively rare, patients still need to pay attention, especially during the initial period of medication or during dose adjustment.

For patients with non-segmental vitiligo, side effects observed in clinical trials include acne, itching, and nasopharyngitis at the application site, as well as headache, urinary tract infection, erythema at the application site, and fever. The incidence of these side effects is low, but patients should consult their doctor promptly if they experience significant discomfort.

More serious side effects include infections, malignant tumors, and lymphoproliferative diseases. Because ruxolitinib is an immunomodulator, it may have effects on a patient's immune system that could increase the risk of infection. In addition, cardiovascular events, thrombosis, thrombocytopenia, anemia, and neutropenia are also listed as warnings and precautions, and these conditions should be closely monitored when using this drug.

Patients using ruxolitinib ointment need to be treated under the guidance of a doctor. If serious side effects occur, the drug should be discontinued and evaluated in time. After recovery, depending on the severity of the condition, dose reduction or permanent discontinuation may be considered. At the same time, patients should also undergo regular examinations during use to ensure their own health.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24da5509-6631-4795-9d42-273faecd08e7